

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
12 June 2025 (12.06.2025)



(10) International Publication Number
WO 2025/120097 A1

(51) International Patent Classification:

C12N 5/0784 (2010.01) C12N 15/113 (2010.01)
C12N 15/86 (2006.01)

(21) International Application Number:

PCT/EP2024/084945

(22) International Filing Date:

05 December 2024 (05.12.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

23214468.3 05 December 2023 (05.12.2023) EP
24198417.8 04 September 2024 (04.09.2024) EP

(71) Applicant: **ASGARD THERAPEUTICS AB** [SE/SE];
Medicon Village, 223 81 Lund (SE).

(72) Inventors: **ROSA, Fábio Alexandre Fiúza**; Rua do Brejo nº53, Touria, Pousos, 2410-205 Leiria (PT). **ARH, Nejc**; Dobovičnikova ulica 14, 1360 Vrhnika (SI). **VAZ, Beatriz Lourenço**; Rua João Pereira Caldas, nº830, 4950 Cambezes – Monção, Viana do Castelo (PT). **PEREIRA, Filipe**; Rua João Batista da Silva nº390, Moledo, 4910-264 Caminha (PT). **XIE, Lihan**; Flygelvägen 115, 224 72 Lund (SE).

(74) Agent: **HØIBERG P/S**; Adelgade 12, 1304 Copenhagen K (DK).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
— with sequence listing part of description (Rule 5.2(a))
— in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: RNA-BASED STRATEGIES FOR DENDRITIC CELL REPROGRAMMING AND USES THEREOF

(57) Abstract: The present invention relates to compositions comprising RNAs, uses thereof, and RNA-based gene expression methods for reprogramming cells to type 1 conventional dendritic cells or antigen-presenting cells. The invention further relates to cells, reprogrammed cells, and uses thereof.

WO 2025/120097 A1